Myriad gains from strong diagnostic sales
This article was originally published in Clinica
Myriad Genetics continues to benefit from its fast-growing molecular diagnostics business, which helped the company achieve high double-digit revenue growth and significantly narrow its net loss for fiscal 2007.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.